// App-Quantinova.ai

2509 : Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).

Researchers

Presenter

  • George R. Blumenschein

Principal Investigators

  • Raffit Hassan

  • Kathleen N. Moore

  • Alessandro Santin

  • Hedy L. Kindler

  • John J. Nemunaitis

  • Shelly Marie Seward

  • Prabhu Rajagopalan

  • Annette Walter

  • Nenad Sarapa

  • Johanna C. Bendell

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Yale School of Medicine, Orange, CT

  • The University of Chicago Medical Center, Chicago, IL

  • Mary Crowley Cancer Research Centers, Dallas, TX

  • Wayne State University- Karmanos Cancer Inst, Huntington Woods, MI

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer Pharma AG, Berlin, Germany

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gynaecological cancer

  • Mesothelioma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • anetumab ravtansine

Outcome

  • Unknown

Study Design

  • Randomized

  • Cohort

Phase

  • I

Study Id's

  • NCT01439152

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved